People with ADHD may be facing more than focus problems and restless energy. A large review suggests the condition is tied to a much higher risk of early death, while prescription medication may be linked to a lower risk.
The research pulled together 19 observational studies covering nearly 16 million people across three continents. That broad scope gave researchers a strong look at long-term patterns, even if the studies could not prove direct cause and effect.
Overall, people diagnosed with ADHD had about a 71% higher risk of dying early than those without the condition. The review looked at both natural causes, like heart disease and diabetes, and unnatural causes, including suicide and injuries.
The numbers were stark. Suicide risk was nearly doubled, rising 89%, while deaths from intentional or unintentional injuries, such as car crashes, were 55% higher.
Natural causes also played a major role, with a 27% higher risk of death in that category. Researchers said that long-term health issues, smoking, substance use, and the daily struggle of managing appointments and treatment plans may all be part of the picture.
That’s where medication stood out. In one analysis, people with ADHD who were taking prescribed medication had a 25% lower risk of death from any cause than those who were not treated.
The findings do not mean medication is a magic fix, but they do hint that treatment may help blunt some of the risks that build up over time. Better symptom control can make it easier to stay organized, follow medical advice, and keep up with routine care.
Experts involved in the review stressed that ADHD itself is not automatically a life-shortening diagnosis. With the right support, many people can live long, healthy lives and manage the condition effectively.
Still, the pattern matters. ADHD can affect planning, impulse control, and day-to-day self-management, which may help explain why both accidental harm and untreated health problems show up more often in these studies.
The review also had clear limits. Every study included was observational, so the results show associations rather than proof that ADHD directly causes earlier death.
The medication finding was based on only three of the 19 studies, which makes it promising but still early. Differences in diagnosis, healthcare access, and how researchers tracked outcomes also made the results uneven across datasets.
Other factors were not consistently accounted for, including income, other mental health conditions, and social stressors. That means the real-world picture is likely more complicated than any single statistic can capture.
Even with those cautions, the review adds weight to a message that has been building for years: ADHD deserves serious attention, not casual dismissal. Treatment, follow-up, and access to care may matter just as much as the diagnosis itself.
That is especially important for adults, where ADHD can fly under the radar for years while health habits and daily routines slowly slip. When the condition is recognized and treated, the difference can reach far beyond concentration and classroom performance.
